Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | FES | P07332 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1836724 | 0.89 | NAMPT (0.48) | PLK1NAMPTGAAMTOR | |
| SCHEMBL4028183 | 0.84 | PLK1 (0.47) | PLK1GAAKDM4ENPC1RAB9A | |
| SCHEMBL1703629 | 0.83 | PLK1 (0.50) | PLK1GAALMNAKMT2AKDM4E | |
| SCHEMBL12077218 | 0.82 | NAMPT (0.45) | PLK1NAMPTGAALMNAKMT2A | |
| SCHEMBL13046649 | 0.80 | CYP2C19 (0.55) | PLK1GAALMNAKMT2AKDM4E | |
| SCHEMBL12077483 | 0.80 | NAMPT (0.53) | PLK1NAMPTHDAC1 | |
| SCHEMBL12077659 | 0.78 | NAMPT (0.48) | PLK1NAMPTGAAFESFGFR1 | |
| SCHEMBL13276780 | 0.78 | PLK1 (0.41) | PLK1NAMPTGAALMNAKMT2A | |
| SCHEMBL12077059 | 0.76 | NAMPT (0.53) | PLK1NAMPTGAALMNAKMT2A | |
| SCHEMBL12092493 | 0.76 | NAMPT (0.62) | PLK1NAMPTGAALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | claimed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| EP-2318369-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TopoTarget A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156421-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | TOPOTARGET A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | SUCNR1, NAMPT, NAPRT | PLK1 2489/4885NAMPT 2/4885GAA 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.